Replies to post #86452 on Biotech Values

[DewDiligence]

ITMN ACHN IDIX:

I view this new [liver tox] issue with ITMN-191 as a slightly positive development for ACHN inasmuch as I think any safety issues with any of the HCV PIs in front of ACHN's ACH-1625 should be viewed positively.

Agreed. It’s also slightly bullish for IDIX for the same reason.

The ACH-1625 program appears to be running ahead of the original schedule—the phase-1b monotherapy study is expected to be completed by the end of 2009 (vs the original guidance of 1Q10). If the results are good, ACHN will undoubtedly strive to disseminate the top-line data at the JPM conference in January.